iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
Using our synthetic shuttle platform, we aim to unlock previously undruggable intracellular targets, broaden therapeutic windows, and expand treatment options for patients across a range of indications. The company is focused on advancing its pipeline toward the clinic while building scalable value through strategic partnerships.
Many of the most critical cancer drivers are located inside tumor cells, yet existing therapies often struggle to effectively and selectively deliver drugs into the cytosol. As a result, key intracellular cancer targets remain largely inaccessible. Furthermore, certain treatment modalities such as chemotherapy or antibody-drug conjugates rely on cellular internalization to exert their anti-tumor effect. Their typical uptake mechanism via endocytosis often results in endosomal entrapment and subsequent degradation of the active compound, leading to low intracellular drug levels that limit efficacy and durability of anti-tumor responses.
Our platform enables direct cytosolic delivery of diverse therapeutic payloads, spanning small and large molecules, into patients’ tumor cells through a unique, uptake mechanism upregulated in tumors. This mechanism has been observed to be highly active in multiple cancer types, supporting a broad potential application in solid tumors.
The iDEL platform is a modular, synthetic shuttle system designed to transport therapeutic payloads directly into the cytosol of tumor cells. Unlike conventional delivery approaches that rely on receptor-limited uptake or face challenges by endosomal entrapment, iDEL leverages a pan-tumor shuttle mechanism to enable efficient intracellular delivery across clinically relevant cancer types, including heterogeneous tumors.
PIPELINE
Building on our shuttling platform, we are advancing a focused pipeline of oncology treatments and exploring additional possibilities to improve cancer therapies.
For our two proprietary lead candidates, we are currently expanding preclinical proof-of-concept data to support progression toward clinical evaluation. These include:
Lead Candidate #1
Intracellular oncogen targeting
Lead Candidate #2
Multicancer drug conjugate
Experienced leadership at the intersection of science and drug development
iDEL Therapeutics is supported by a syndicate of life science investors and partners
We are seeking partners to jointly expand therapeutic possibilities and increase patient benefit across cancer indications. Our versatile plug-and-play platform enables the delivery of a wide spectrum of payloads, from small molecules, peptides and nanobodies, up to large molecules.
March 23-25, 2026
Participant: Dr. Jürgen Moll, CSO &
Dr. Torsten Mummenbrauer, CBO
Lisbon, Portugal
March 25-26, 2026
Participant: Dr. Jürgen Moll, CSO &
Dr. Torsten Mummenbrauer, CBO
Lisbon, Portugal
April 21-22, 2026
Participant: Dr. Marcus Kostka, CEO
Presentation: April 22, 2026
03:12 pm - Weißer Saal
New Kids on the Block in Medical Biotech
Leipzig, Germany
May 4-6, 2026
Participant: Dr. Marcus Kostka, CEO &
Dr. Jürgen Moll, CSO
Company Presentation
Prague, Czech Republic
